Background & Aims: Nonalcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease for which there is limited therapy available. Insulin sensitizing, anti-inflammatory, and antifibrotic properties of thiazolidinediones support their use in treating NASH. We have evaluated pioglitazone in the treatment of nondiabetic patients with NASH. Methods: We randomized 74 nondiabetic patients (45 men; median age, 54 y) with histologically proven NASH to 12 months of standard diet, exercise, and either placebo or pioglitazone (30 mg/day). Sixty-one patients (30 placebo, 31 pioglitazone) had liver biopsies both at the beginning and the end of the study. Results: Compared with placebo, pioglitazone therapy was associated with an increase in weight (mean change, ؊0.55 vs ؉2.77 kg; P ‫؍‬ .04) and a reduction in glucose (؉0.4 vs ؊0.1 mmol/L; P ‫؍‬ .02), HbA1c (؉0.16% vs ؊0.18%; P ‫؍‬ .006), insulin C peptide level (؉42 vs ؊78 pmol/L; P ‫؍‬ .02), alanine aminotransferase level (؊10.9 vs ؊36.2 u/L; P ‫؍‬ .009), ␥-glutamyltransferase level (؊9.4 vs ؊41.2 u/L; P ‫؍‬ .002), and ferritin (؊11.3 vs ؊90.5 g/L; P ‫؍‬ .01). Histologic features including hepatocellular injury (P ‫؍‬ .005), Mallory-Denk bodies (P ‫؍‬ .004), and fibrosis (P ‫؍‬ .05) were reduced in patients treated with pioglitazone compared with those in the placebo group. Conclusions: Pioglitazone therapy over a 12-month period in nondiabetic subjects with NASH resulted in improvements in metabolic and histologic parameters, most notably liver injury and fibrosis. Larger extended trials are justified to assess the long-term efficacy of pioglitazone in this patient group.
N onalcoholic fatty liver disease (NAFLD) encompasses a spectrum of conditions ranging from simple hepatic steatosis through steatosis associated with varying degrees of hepatocellular injury, inflammation, and fibrosis; cirrhosis; and hepatocellular carcinoma. 1 NAFLD currently affects about 30% of the population 2 in affluent societies and is a burgeoning problem in the developing world. Up to a quarter of people with NAFLD may have nonalcoholic steatohepatitis (NASH), 3 considered the advanced form of NAFLD with the propensity to progress. As conditions associated with NAFLD such as type 2 diabetes and obesity continue to reach epidemic proportions, it is expected that NASH will represent an increasingly important global public health problem.
Although there is no universally accepted pharmacologic treatment for NASH, its association with insulin resistance 4, 5 has provided the rationale for evaluating medical therapies that increase insulin sensitivity. Pioglitazone is a member of the thiazolidinedione family of antidiabetic agents that stimulate the peroxisome proliferator-activated receptor-␥. Activation of peroxisome proliferator-activated receptor-␥ reduces the hepatic supply of fatty acids from adipose tissue 6 and increases ␤-oxidation by direct activation of AMP kinase. 7 It also improves the adipokine profile of NASH patients by increasing adiponectin levels, 8 whereas at the same time reducing proinflammatory cytokine production. All of these effects could reduce hepatic fat accumulation and related inflammation. In addition, thiazolidinediones have been shown to restore the quiescent phenotype of hepatic stellate cells in culture and to reduce activated stellate cell numbers in rodent models of NASH. 9 Therefore, pioglitazone has a potential to reduce hepatic fibrosis that is associated with NASH. A recent proof-of-concept study showed a reduction in both hepatic fat and inflammation in diabetic NASH patients taking pioglitazone. 10 We report the results of a randomized, double-blind, placebocontrolled trial of 1 year of pioglitazone 30 mg/day in nondiabetic subjects with NASH.
tingham Joint Ethics Committee. (National Research Register Document: N0192119052; ISRCTN: 10319160.) Takeda Pharmaceuticals UK provided the pioglitazone and placebo tablets for this investigator-initiated study.
Subjects
Patients between the ages of 18 and 70 years who were able to give written consent were screened initially by medical history and physical examination. Those with any history of alcohol excess (weekly consumption: men, Ͼ210 g; women, Ͼ140 g) were excluded. Exclusion of other liver diseases was made by detailed investigations including hepatitis B and C serology, iron studies (ferritin, transferrin saturation), ␣-1 antitrypsin, ceruloplasmin, auto-antibody profiles, and immunoglobulins. Patients who were taking drugs associated with fatty liver (eg, methotrexate, amiodarone, tamoxifen, valproate, and so forth) and those with diabetes mellitus diagnosed either before or at the time of recruitment (2 fasting venous plasma glucose levels Ն7 mmol/L) were excluded. Patients taking lipid-lowering drugs (4 subjects) were enrolled if the dose had been stable for at least 3 months before the run-in period. Each patient had an ultrasound examination of the liver. Liver biopsy was performed according to standard protocol. Diagnosis of NASH was confirmed on histology by the presence of fat plus evidence of hepatocyte injury and inflammation or fibrosis. 11 Patients with only hepatic steatosis were not recruited for the trial. Other exclusion criteria included taking weight-reduction medication, pregnant or lactating women, those with current or previous heart failure, and those with renal impairment.
Design
All participants entered a 3-month run-in period before randomization during which they were seen by a dietician and were instructed to reduce their calorie intake by 500 Kcal/day as well as to perform modest exercise (such as walking, swimming, gardening, and so forth) regularly for 30 -40 minutes per day at least 5 days per week. The advice regarding diet and exercise was reinforced during each follow-up visit. Randomization was performed via the arand computer program (Pharmacy department, University Hospitals NHS Trust, Nottingham, UK) in blocks of 4. Information collected at the time of randomization included anthropometric data (height, weight, waist-hip ratio), blood count, standard liver chemistry, and fasting blood samples for the determination of glucose, insulin, HbA1c, and lipids (highdensity lipoprotein and low-density lipoprotein cholesterol, and triglyceride levels). Serum insulin and C-peptide levels were measured on an Immulite 2000 (Diagnostic Products Corporation, Llanberis, Caernarfon Gwynedd, UK) by a 2-site immunometric assay or competitive immunoassay, respectively. Interassay coefficients of variation for these assays were less than 10%.
Quantitative assessment of insulin sensitivity was performed using the readily accessible homeostasis model assessment (homeostasis model assessment-insulin resistance (IR) ϭ fasting insulin ϫ fasting glucose/22.5). 12 Adiponectin and leptin levels were estimated using cytokine multiplex assays on 50 L of plasma according to the manufacturer's recommendations (Invitrogen Ltd, Paisley, UK).
Based on a 15% placebo response and a 50% response to pioglitazone based on a previous study using metformin for NASH, 13 the power calculation (␣ ϭ 0.8, ␤ ϭ 0.05) required 33 patients in each group. To allow for a 15% drop-out rate, we aimed to enroll 75 patients. One subject was found to be diabetic at the time of randomization and therefore was excluded at this stage. Primary outcomes were reductions in hepatocyte injury and fibrosis scores on histology. Secondary outcomes were improvements in the biochemical and metabolic parameters in the pioglitazone group.
Seventy-four patients were randomized to receive either 30 mg/day of pioglitazone or placebo for 12 months. Monitoring of weight, waist-hip ratio, blood count, standard liver chemistry, and adverse events was performed at 2-month intervals during the study. At each 4-month visit, a brief physical examination was performed, in particular to look for any adverse events. Compliance was monitored at the 4-month visit by using a tablet count. At the end of 12 months of follow-up evaluation, we measured weight, waist-hip ratio, blood count, standard liver chemistry, fasting glucose level, insulin level, HbA1c level, and full lipid profile, and we also repeated the liver ultrasound scan. After these an end-of-treatment liver biopsy was performed.
All clinical and laboratory data were collected in a double-blind manner. Liver biopsy specimens were graded and staged according to the NASH histologic scoring system (as previously described by Promrat et al 14 ) by a single pathologist (P.V.K.) who was blinded to patient details, treatment group, and sequence of biopsy. Briefly, in this system, steatosis, hepatocyte injury, parenchymal inflammation, portal inflammation, and Mallory bodies are graded as independent variables (summarized in Table 1 ) and fibrosis is scored on a 0 -4 scale, identical to that proposed by Brunt et al. 15 The categories are similar to the Clinical Research Network system, 16 although the latter has fewer grades in each category. Because our primary outcomes were changes in hepatocellular injury and fibrosis scores we did not use the NAFLD Activity Score, which is just an unweighted sum of steatosis, lobular inflammation, and ballooning. 16 
Statistical Analysis
Categoric data are expressed as frequencies (and percentages). Continuous variables are summarized as mean Ϯ 1 standard deviation. Changes within each group over the study period were evaluated using the paired t test (for normally distributed data) or the Wil-coxon signed rank test (for nonparametric data). Comparisons between groups were made using the MannWhitney U test.
Results
Baseline characteristics were similar for the 2 groups except for lower alkaline phosphatase and fasting insulin levels in the pioglitazone-treated group (Tables  2-4) . Although the mean ␥-glutamyltransferase (GGT) level appears higher in the pioglitazone group, the 2 study groups were not significantly different in this respect.
Liver Histology
Overall, 123 of 135 (91.1%) liver biopsies were considered adequate (Ն15 mm in length, 1.4-mm wide, and Ն5 portal tracts). 17 In the placebo group, steatosis was reduced (P ϭ .03), whereas the injury score increased (P ϭ .04) over the 12-month period. Treatment with pioglitazone was associated with a reduction in steatosis (P ϭ .001), injury (P ϭ .09), lobular inflammation (P ϭ .04), Mallory bodies (P ϭ .005), and fibrosis (P ϭ .006). Compared with placebo-treated patients, pioglitazone was associated with a reduction in hepatocyte injury (P ϭ .005), Mallory bodies (P ϭ .004), and fibrosis (P ϭ .05) ( Table 2 ). Figure 1 illustrates the change in liver histology scores resulting from 12 months of treatment with either pioglitazone or placebo.
Clinical and Biochemical Parameters
In the placebo arm, we observed reductions in diastolic blood pressure (P Ͻ .001) and alanine aminotransferase level (ALT) (P ϭ .02), whereas the fasting glucose level (P ϭ .002) increased in this group (Table 3 ). In the pioglitazone group, weight increased (P ϭ .005) whereas diastolic blood pressure (P ϭ .008), low-density lipoprotein cholesterol (P ϭ .04), bilirubin level (P ϭ .003), ALT level (P Ͻ .001), GGT level (P Ͻ .001), and ferritin level (P ϭ .02) decreased (Table 3) .
Compared with the placebo group, pioglitazonetreated patients gained weight (P ϭ .02); however, the fasting glucose level (P ϭ .02), ALT level (P ϭ .009), GGT level (P ϭ .002), and ferritin level (P ϭ .01) all improved (Table 3 ). An apparent increase in homeostasis model assessment-IR in the pioglitazone group was not statistically significant.
Fasting insulin levels were similar for both groups, whereas the C peptide level was reduced significantly after pioglitazone treatment compared with placebo (P ϭ .02) ( Table 4 ). There was also an increase in serum leptin levels in the pioglitazone group (P ϭ .08) compared with the placebo group (Table 4) .
Withdrawals and Side Effects
Seven subjects from the placebo arm withdrew (3 for personal reasons, 1 with right upper-quadrant pain, 1 because of weight gain, 1 because of a rash, and 1 because of vertigo), and 6 subjects from the treatment arm withdrew (2 were found to be diabetic after randomization, 2 withdrew for personal reasons, 1 because of diarrhea and vomiting, and 1 because of headaches and epistaxis). We have listed the adverse events reported in both groups in Table 5 . Fluid retention was observed in 2 subjects, both from the pioglitazone group. None of the subjects developed heart failure or fractures during the study period. Bone mineral density was not monitored routinely as a part of this study.
A verbal account of the previous week's diet and exercise patterns at the 4-month review during the study period suggested that 18 of 30 subjects in the placebo group and 14 of 31 subjects in the pioglitazone group had been fully complaint (during all of the 3 follow-up visits) with the lifestyle advice; the rest of the subjects were considered partly compliant (at 1 or 2 follow-up 
Discussion
This was a randomized controlled trial evaluating a pharmacologic treatment for NASH in exclusively nondiabetic subjects. We have shown that treatment with pioglitazone 30 mg over a 12-month period reduced the degree of steatosis, hepatocellular injury, lobular inflammation, Mallory-Denk bodies, and fibrosis. Although hepatic steatosis improved in the placebo group, hepatocellular injury (representing ballooning degeneration, apoptosis, and drop-out hepatocytes) worsened during the study period. Ballooning is a structural manifestation of 
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microtubular disruption leading to severe cell injury, and apoptosis is a well-recognized contributing process in many chronic progressive liver diseases including NASH. 18 Ballooning, Mallory-Denk bodies, and fibrosis are the key histologic features that predict the progression of NASH to cirrhosis and the resulting complications, including liver-related deaths. 1, 19 In contrast to placebo, pioglitazone therapy was associated with a reduction in these histologic predictors of progressive disease. Therefore, long-term pioglitazone therapy may arrest or reverse the progression of NASH and improve its clinical outcome. A modest reduction in ALT levels occurred in our placebo group and this was associated with a reduction in the degree of steatosis on histology. Reductions in ALT and GGT levels may be related to the lifestyle modifications 20,21 as was used for both the placebo and pioglitazone-treated patients during our run-in period. A significant reduction in hepatic steatosis has been reported previously among NASH patients receiving a placebo in a randomized controlled trial of ursodeoxycholic acid therapy, 22 suggesting this may either be related to lifestyle modifications or part of the natural history of NASH. It is unclear, however, whether a reduction in liver enzyme levels on its own is associated with an improved clinical outcome. When combined with other noninvasive markers, ALT levels have been shown to be associated with advanced histologic changes in some studies. 23, 24 However, advanced histologic changes in NAFLD can exist despite normal liver enzyme levels 25 and changes in aminotransferase levels do not parallel the progression of fibrosis. 26 In our study, a reduction in ALT level in the placebo group was associated with increased features of hepatocellular injury during the 12-month period. Patients in the pioglitazone group had a more marked reduction in ALT and GGT levels than the placebo group and a concurrent improvement in the degree of steatosis, hepatocellular injury, lobular inflammation, MalloryDenk bodies, and fibrosis. Previous pilot studies have reported beneficial effects of thiazolidinediones in the treatment of NASH. Troglitazone (which has since been withdrawn from the market) was shown to normalize liver enzyme levels in patients with NASH. 27 Open-label pilot studies including a small number of subjects have reported that rosiglitazone 28 and pioglitazone therapy 14 can improve histologic features of NASH. A study of 30 patients with NASH, treated for 48 weeks with rosiglitazone, showed a reduction in hepatocellular ballooning and perisinusoidal fibrosis, although its overall effect on fibrosis stage could not be determined. 28 Another pilot study that included 18 nondiabetic subjects treated with pioglitazone showed an improvement in all histologic features including fibrosis. 14 A proof-of-concept study involving 55 subjects with NASH and either impaired glucose tolerance or diabetes showed a reduction in steatosis and inflammation but not fibrosis after 6 months of treatment with pioglitazone. 10 In summary, previous studies have either had no placebo arm 14, 27, 28 or had a short duration of treatment. 10 The current study was powered to detect improvement in important histologic parameters and 12 months of therapy was considered an adequate period to assess the effect of the drug on hepatic fibrosis. Consistent with our hypothesis, none of the subjects receiving pioglitazone had worsening of their fibrosis score, whereas the treatment resulted in a reduction in a significant proportion of subjects.
This study shows the benefit of the antidiabetic agent pioglitazone in treating nondiabetic patients with NASH and the effect appears to be similar to that seen in diabetic patients. 10 After 12 months of treatment, fasting plasma glucose and HbA1C levels increased in the placebo group, whereas they improved in the pioglitazone group. We found no significant reduction in fasting insulin level or improvement in homeostasis model assessment-IR in the pioglitazone group. This may be because patients with diabetes were excluded from the study and a relatively low dose (30 mg) of pioglitazone was used. A significant decrease in C peptide levels in the pioglitazone-treated patients, however, suggests that the drug still acts by improving insulin sensitivity and hence reduced insulin secretion. In addition, there was a modest increase in serum adiponectin levels after treatment with pioglitazone (P ϭ .08). Adiponectin secreted by visceral adipocytes correlates strongly with insulin sensitivity. 29 The increase in serum adiponectin levels during pioglitazone therapy may be mediated through peroxisome proliferator-activated receptor-␥-mediated transcriptional activation of the adiponectin gene 30 and this action may account for some of the beneficial effects of the pioglitazone. 31 In contrast, serum leptin levels increased significantly in patients receiving pioglitazone, which probably reflects the weight gain seen in this group. Although leptin may play a role in the development of fibrosis in NASH, 32 this may occur only in the presence of other cofactors such as alcohol or hepatitis C. 33 Serum resistin levels did not change in either group, consistent with the fact that the association of this adipokine with insulin resistance is weak in human beings. 34 Pioglitazone treatment was well tolerated without any excess in adverse events over placebo. However, the dropout rate was slightly higher (17.5%) than expected during power calculation (15%) in our power calculation. It can be argued that the exclusion of 13 subjects (who did not have the end-of-treatment biopsies) could have selectively excluded subjects with worsening of NASH in the pioglitazone group and hence, lead to the demonstration of a beneficial effect of the drug. However, the design of the randomized controlled trial and blinding of the histopathologist during the formal scoring of histologic parameters would have largely avoided any systematic bias. In addition, the withdrawal rate was similar in both study groups and those who withdrew in either group did so because of a wide variety of reasons (listed in the Results section), most of which cannot be linked to the severity of liver disease.
As shown in previous studies including diabetic subjects, 35, 36 pioglitazone therapy was associated with signif- icant weight gain. We observed a reduction in fibrosis after pioglitazone treatment, suggesting that the weight gain secondary to the drug did not nullify its beneficial effect on NASH. In addition, the proportion of subjects with dyslipidemia (according to treatment guidelines from the National Institute of Clinical Excellence) 37 increased by 4% in the placebo group and decreased by 15% in the pioglitazone group (P ϭ .05). No difference in mean serum lipid measurements was observed between the 2 groups (Table 3) . Whether beneficial effects of pioglitazone on liver histology in NASH and other components of metabolic syndrome outweigh its effect on body weight is unclear. Considering that cardiovascular events are still the most common cause of morbidity and mortality in subjects with metabolic syndrome, including those with NASH, 1, 38 larger clinical trials are needed to study the effect of the drug on long-term clinical end points. Although recent analysis of data regarding cardiovascular outcomes on rosiglitazone has prompted concern regarding the safety of thiazolidinediones, 39 pioglitazone has been shown to lower the risk of death, myocardial infarction, or stroke among a diverse population of patients with diabetes, 40, 41 indicating that the reported deleterious outcomes are not a class effect.
In conclusion, 12-month treatment with pioglitazone therapy was associated with a reduction in hepatocellular injury and fibrosis in patients with NASH. Larger extended trials are justified to assess the long-term efficacy of pioglitazone in this patient group. The ultimate end points would be averting cirrhosis and the ensuing complications and also improving the metabolic profile and therefore cardiovascular disease in the rapidly growing NASH population.
